Conventional hepatitis B vaccine contains alum but is less effective to induce Th1 response. Selenium nanoparticles and Bacillus Calmette–Guerin were reported as immune modulators. In this study, SeNPs were extracted from Mycobacterium bovis and characterised. SeNPs were mixed with HBs-Ag and administered to the mice to investigate he immune response pattern. With an addition of Se ions at a sub-inhibitory concentration to the Sauton medium broth after 24 h, SeNPs were extracted from M. bovis and characterised by Fourier transform infrared spectroscopy, dynamic light scattering, atomic forcemicroscopy, energy dispersive X-ray spectrum, transmission electron microscopy, and thermogravimetric analysis. Furthermore, female inbred BALB/c mice were injected subcutaneously on the first, 14th, 28th day with 100 and 200 µg doses of that SeNPs supplemented with HBs-Ag vaccine. Later, the total antibody, isotypes of Immunoglobulin G1, Interlukin 4, and interferon-γ were measured by enzye-linked immunosorbent assay. The size of the SeNPs was <150 nm. Level of total antibody and immunoglobulin G2a increased significantly in the group that received 200 µg/ml nano selenium extracted from M. bovis. SeNPs in dose of 200 µg coated with organic materials of M. bovis could induce an influential immune response in relation to the conventional HBs-Ag vaccine.

References

1. 1)
  - 19. Yazdi, M.H., Mahdavi, M., Varastehmoradi, B., et al: ‘The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study’, Biol. Trace Elem. Res., 2012, 149, (1), pp. 22–28.
2. 2)
  - 4. Koumbi, L., Karayiannis, P.: ‘The epigenetic control of hepatitis B virus modulates the outcome of infection’, Front. Microbiol., 2016, 6, pp. 1491.
3. 3)
  - 17. Li, Q., Normolle, D.P., Sayre, D.M., et al: ‘Immunological effects of BCG as an adjuvant in autologous tumor vaccines’, J. Clin. Immunol., 2000, 94, (1), pp. 64–72.
4. 4)
  - 5. Koike, Y., Yoo, Y.C., Mitobe, M., et al: ‘Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine’, Vaccine, 1998, 16, (20), pp. 1982–1989.
5. 5)
  - 15. Kundi, M.: ‘New hepatitis B vaccine formulated with an improved adjuvant system’, Expert Rev. Vaccines, 2007, 6, (2), pp. 133–140.
6. 6)
  - 6. Cardell, K.: ‘Studies on hepatitis B vaccination and factors associated with the vaccine response’, 2009.
7. 7)
  - 29. Dezfuli, H.T., Shahbazzadeh, D., Eidi, A., et al: ‘Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin’, Gastroenterol. Hepatol. Bed Bench, 2014, 7, (2), p. 108.
8. 8)
  - 22. Yazdi, M.H., Varastehmoradi, B., Faghfuri, E., et al: ‘Adjuvant effect of biogenic selenium nanoparticles improves the immune responses and survival of mice receiving 4T1 cell antigens as vaccine in breast cancer murine model’, J. Nanosci. Nanotechnol., 2015, 15, (12), pp. 10165–10172.
9. 9)
  - 1. Alavian, S.M.: ‘Networking for overcoming on viral hepatitis in Middle East and Central Asia: Asian hepatitis network’, Hepat. Mon., 2007, 7, (4), pp. 181–182.
10. 10)
  - 10. Lin, Y.C., Chang, M.-H., Ni, Y.H., et al: ‘Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan’, J. Infect. Dis., 2003, 187, (1), pp. 134–138.
11. 11)
  - 25. Plotkin, S.A.: ‘Correlates of protection induced by vaccination’, Clin. Vaccine Immunol., 2010, 17, (7), pp. 1055–1065.
12. 12)
  - 20. Mahdavi, M., Mavandadnejad, F., Yazdi, M.H., et al: ‘Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model’, J. Infect. Public Health, 2016, doi: 10.1016/j.jiph.2016.02.006.
13. 13)
  - 11. Whittle, H., Pilkington, J., Maine, N., et al: ‘Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages’, Lancet, 1995, 345, (8957), pp. 1089–1092.
14. 14)
  - 26. Amanna, I.J., Slifka, M.K.: ‘Contributions of humoral and cellular immunity to vaccine-induced protection in humans’, Virology, 2011, 411, (2), pp. 206–215.
15. 15)
  - 28. Byars, N.E., Nakano, G., Welch, M., et al: ‘Improvement of hepatitis B vaccine by the use of a new adjuvant’, Vaccine, 1991, 9, (5), pp. 309–318.
16. 16)
  - 9. Mohan, T., Verma, P., Rao, D.N.: ‘Novel adjuvants & delivery vehicles for vaccines development: a road ahead’, Indian J. Med. Res., 2013, 138, (5), p. 779.
17. 17)
  - 14. Stephenson, R., You, H., McManus, D.P., et al: ‘Schistosome vaccine adjuvants in preclinical and clinical research’, Vaccines, 2014, 2, (3), pp. 654–685.
18. 18)
  - 27. Lan, Q., Zheng, T., Rothman, N., et al: ‘Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma’, Blood, 2006, 107, (10), pp. 4101–4108.
19. 19)
  - 24. Snapper, C.M., Paul, W.E.: ‘Interferon-and B cell stimulatory factor-1 reciprocally regulate Ig isotype production’, Science, 1987, 236, (4804), pp. 944–947.
20. 20)
  - 16. Yoo, Y.C., Hata, K., Lee, K.B., et al: ‘Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice’, Arch. Pharm. Res., 2002, 25, (4), pp. 522–527.
21. 21)
  - 13. Levast, B., Awate, S., Babiuk, L., et al: ‘Vaccine potentiation by combination adjuvants’, Vaccines, 2014, 2, (2), pp. 297–322.
22. 22)
  - 3. Aspinall, E., Hawkins, G., Fraser, A., et al: ‘Hepatitis B prevention, diagnosis, treatment and care: a review’, Occup. Med., 2011, 61, (8), pp. 531–540.
23. 23)
  - 12. Borges, O., Silva, M., de Sousa, A., et al: ‘Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen’, Int. Immunopharmacol., 2008, 8, (13), pp. 1773–1780.
24. 24)
  - 8. Taniyama, T., Watanabe, T., Azuma, I., et al: ‘Adjuvant activity of mycobacterial fractions’, Jpn. J. Microbiol., 1974, 18, (6), pp. 415–426.
25. 25)
  - 23. Dittmer, U., Peterson, K.E., Messer, R., et al: ‘Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to friend retrovirus infection’, J. Virol., 2001, 75, (2), pp. 654–660.
26. 26)
  - 21. Lukac, N., Massányi, P.: ‘Effects of trace elements on the immune system’, Epidemiol. Microbiol. Immunol., 2007, 56, (1), pp. 3–9.
27. 27)
  - 18. Shirsat, S., Kadam, A., Naushad, M., et al: ‘Selenium nanostructures: microbial synthesis and applications’, RSC Adv., 2015, 5, (112), pp. 92799–92811.
28. 28)
  - 2. Bhattacharya, D., Thio, C.L.: ‘Review of hepatitis B therapeutics’, Clin. Infect. Dis., 2010, 51, (10), pp. 1201–1208.
29. 29)
  - 7. Oleszycka, E., Lavelle, E.C.: ‘Immunomodulatory properties of the vaccine adjuvant alum’, Curr. Opin. Immunol., 2014, 28, pp. 1–5.

Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study

References

Related content